选择语言

Recombinant Monoclonal Anti-PSMA Antibody, Rabbit (9A2)

用户评价
货号-规格
价格
Qty.

HGS-S317-20ul
¥1280.00

HGS-S317-100ul
¥4450.00
合计0件 产品金额¥ 0

产品详情

  • 描述/背景(Background)

    Recombinant Monoclonal Anti-PSMA Antibody, Rabbit (9A2) is a PSMA primary antibody for IHC application. PSMA is transmembrane glycoprotein belonging to the M28 peptidase family. The protein acts as a glutamate carboxypeptidase on different alternative substrates, including the nutrient folate and the neuropeptide N-acetyl-l-aspartyl-l-glutamate and is expressed in a number of tissues such as prostate, central and peripheral nervous system and kidney.

  • 产品参数(Product Specifications)

    Host Species
    Rabbit
    Isotype
    IgG
    Clone
    9A2
    Application
    IHC
    Property
    1:1000
    State
    Liquid
    Positive Control
    Human Prostate Tissue
    Clonality
    Monoclonal
    Research Field
    Cancer Drug Targets
    Source
    Rabbit
    Synonym
    PSMA
  • 操作步骤(Experiment Protocol)

    LEICA手工染色操作步骤

  • 储存(Storage)

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. The shelf life is 30 days from the date of opening.

  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

典型数据(Typical Data)
  • 质控样本(Control Sample)

     PSMA CONTROL SAMPLE

    Immunohistochemical analysis of paraffin embedded Human Prostate Tissue labelled with HGS-S317 at 1/1000 dilution.
    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • 肿瘤样本(Cancer Sample)

     PSMA CANCER SAMPLE
     PSMA CANCER SAMPLE
     PSMA CANCER SAMPLE

    Immunohistochemical analysis of paraffin embedded human cancer tissue labelled with HGS-S317 at 1/1000 dilution.
    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

用户评价
发表评论

前沿进展

 
药物研发进展
  • 英文全称:

    Prostate-Specific Membrane Antigen

  • 中文全称:

    前列腺癌特异性膜抗原

  • 种类:

  • 上市药物数量:

    5 详情

  • 临床药物数量:

    102 详情

  • 最高研发阶段:

    临床三期

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价